Ilimaquinone induces death receptor expression and sensitizes human colon cancer cells to TRAIL-induced apoptosis through activation of ROS-ERK/p38 MAPK-CHOP signaling pathways

Food and Chemical Toxicology

Volumn 71, Issue , 2014, Pages 51-59

  Do, Minh Truong ^a   Na, MinKyun ^a   Kim, Hyung Gyun ^a   Khanal, Tilak ^a   Choi, Jae Ho ^a   Jin, Sun Woo ^a   Oh, Seok Hoon ^a   Hwang, In Hyun ^b   Chung, Young Chul ^c   Kim, Hee Suk ^c   Jeong, Tae Cheon ^d   Jeong, Hye Gwang ^a  

^a Chungnam National University   (South Korea)

^b University of Iowa   (United States)

^c International University of Korea   (South Korea)

^d Yeungnam University   (South Korea)

Author keywords

Apoptosis; CHOP; DR4; DR5; Ilimaquinone; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CASPASE 8; CCAAT ENHANCER BINDING PROTEIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; ILIMAQUINONE; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN BCL XL; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; CASPASE 3; DEATH RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; DDIT3 PROTEIN, HUMAN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; PRIMER DNA; QUINONE DERIVATIVE; SESQUITERPENE; TNFSF10 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL; CARBON NUCLEAR MAGNETIC RESONANCE; CELL SURVIVAL; COLON CANCER; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG DETERMINATION; DRUG SENSITIZATION; DRUG STRUCTURE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL TRANSDUCTION; UPREGULATION; ANTINEOPLASTIC ACTIVITY; CELL VIABILITY; HCT116 CELL LINE; MOLECULAR MECHANICS; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; CHEMISTRY; COLON TUMOR; DRUG EFFECTS; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA PRIMERS; ENZYME ACTIVATION; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PROTON MAGNETIC RESONANCE SPECTROSCOPY; QUINONES; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, DEATH DOMAIN; SESQUITERPENES; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION FACTOR CHOP; UP-REGULATION;

EID: 84903443381     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2014.06.001     Document Type: Article

References (40)

1. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science 1998, 281:1305-1308.
2. Bodmer J.L., Holler N., Reynard S., Vinciguerra P., Schneider P., Juo P., Blenis J., Tschopp J. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat. Cell Biol. 2000, 2:241-243.
3. Bourguet-Kondracki M.L., Longeon A., Morel E., Guyot M. Sesquiterpene quinones as immunomodulating agents. Int. J. Immunopharmacol. 1991, 13:393-399.
4. Chawla-Sarkar M., Bae S.I., Reu F.J., Jacobs B.S., Lindner D.J., Borden E.C. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 2004, 11:915-923.
5. Galligan L., Longley D.B., McEwan M., Wilson T.R., McLaughlin K., Johnston P.G. Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol. Cancer Ther. 2005, 4:2026-2036.
6. Gupta S.C., Francis K.S., Nair M.S., Mo Y.Y., Aggarwal B.B. Azapirone, a limonoid tetranortriterpene, induces death receptors and sensitizes human cancer cells to TRAIL through a p53-independent mechanism: evidence for the role of the ROS-ERK-CHOP-death receptor pathway. J. Biol. Chem. 2013, 288:32343-32356.
7. Hwang I.H., Oh J., Kochanowska-Karamyan A., Doerksen R.J., Na M., Hamann M.T. A novel natural phenyl alkene with cytotoxic activity. Tetrahedron Lett. 2013, 54:3872-3876.
8. Ichijo H. From receptors to stress-activated MAP kinases. Oncogene 1999, 18:6087-6093.
9. Jacobson M.D. Reactive oxygen species and programmed cell death. Trends Biochem. Sci. 1996, 21:83-86.
10. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
11. Jimeno J., Lopez-Martin J.A., Ruiz-Casado A., Izquierdo M.A., Scheuer P.J., Rinehart K. Progress in the clinical development of new marine-derived anticancer compounds. Anti-Cancer Drugs 2004, 15:321-329.
12. Kelley S.K., Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr. Opin. Pharmacol. 2004, 4:333-339.
13. Kim J.A., Kim S.K. Bioactive peptides from marine sources as potential anti-inflammatory therapeutics. Curr. Protein Pept. Sci. 2013, 14:177-182.
14. Kim K., Fisher M.J., Xu S.Q., el-Deiry W.S. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res. 2000, 6:335-346.
15. Koschny R., Walczak H., Ganten T.M. The promise of TRAIL - potential and risks of a novel anticancer therapy. J Mol. Med. (Berl.) 2007, 85:923-935.
16. Kurbanov B.M., Fecker L.F., Geilen C.C., Sterry W., Eberle J. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene 2007, 26:3364-3377.
17. Loya S., Hizi A. The interaction of ilimaquinone, a selective inhibitor of the RNase H activity, with the reverse transcriptases of human immunodeficiency and murine leukemia retroviruses. J. Biol. Chem. 1993, 268:9323-9328.
18. Lu P.H., Chueh S.C., Kung F.L., Pan S.L., Shen Y.C., Guh J.H. Ilimaquinone, a marine sponge metabolite, displays anticancer activity via GADD153-mediated pathway. Eur. J. Pharmacol. 2007, 556:45-54.
19. Marcos I.S.C.A., Moro R.F., Basabe P., Diez D., Urones J.G. Quinone/hydroquinone sesquiterpenes. Mini Rev. Org. Chem. 2010, 7:230-254.
20. Oh Y.T., Liu X., Yue P., Kang S., Chen J., Taunton J., Khuri F.R., Sun S.Y. ERK/ribosomal S6 kinase (RSK) signaling positively regulates death receptor 5 expression through co-activation of CHOP and Elk1. J. Biol. Chem. 2010, 285:41310-41319.
21. Park S.K., Sanders B.G., Kline K. Tocotrienols induce apoptosis in breast cancer cell lines via an endoplasmic reticulum stress-dependent increase in extrinsic death receptor signaling. Breast Cancer Res. Treat. 2010, 124:361-375.
22. Prasad S., Yadav V.R., Ravindran J., Aggarwal B.B. ROS and CHOP are critical for dibenzylideneacetone to sensitize tumor cells to TRAIL through induction of death receptors and downregulation of cell survival proteins. Cancer Res. 2011, 71:538-549.
23. Rangel H.R., Dagger F., Compagnone R.S. Antiproliferative effect of ilimaquinone on Leishmania mexicana. Cell Biol. Int. 1997, 21:337-339.
24. Capon Robert J., MacLeod J.K. Revision of the absolute stereochemistry of ilimaquinone. J. Org. Chem. 1987, 52:5059-5060.
25. Senthilkumar K., Venkatesan J., Manivasagan P., Kim S.K. Antiangiogenic effects of marine sponge derived compounds on cancer. Environ. Toxicol. Pharmacol. 2013, 36:1097-1108.
26. Seol D.W., Li J., Seol M.H., Park S.Y., Talanian R.V., Billiar T.R. Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis. Cancer Res. 2001, 61:1138-1143.
27. Shike M., Winawer S.J., Greenwald P.H., Bloch A., Hill M.J., Swaroop S.V. Primary prevention of colorectal cancer. The WHO collaborating centre for the prevention of colorectal cancer. Bull. World Health Organ. 1990, 68:377-385.
28. Song J.J., An J.Y., Kwon Y.T., Lee Y.J. Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance. Involvement of Bcl-xL. J. Biol. Chem. 2007, 282:319-328.
29. Stolfi C., Caruso R., Franze E., Rizzo A., Rotondi A., Monteleone I., Fantini M.C., Pallone F., Monteleone G. 2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression. Mol. Cancer Ther. 2011, 10:1969-1981.
30. Stuckey D.W., Shah K. TRAIL on trial: preclinical advances in cancer therapy. Trends Mol. Med. 2013, 19:685-694.
31. Sung B., Ravindran J., Prasad S., Pandey M.K., Aggarwal B.B. Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL. J. Biol. Chem. 2010, 285:35418-35427.
32. Takizawa P.A., Yucel J.K., Veit B., Faulkner D.J., Deerinck T., Soto G., Ellisman M., Malhotra V. Complete vesiculation of Golgi membranes and inhibition of protein transport by a novel sea sponge metabolite, ilimaquinone. Cell 1993, 73:1079-1090.
33. Taniai M., Grambihler A., Higuchi H., Werneburg N., Bronk S.F., Farrugia D.J., Kaufmann S.H., Gores G.J. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. 2004, 64:3517-3524.
34. van der Sanden M.H., Meems H., Houweling M., Helms J.B., Vaandrager A.B. Induction of CCAAT/enhancer-binding protein (C/EBP)-homologous protein/growth arrest and DNA damage-inducible protein 153 expression during inhibition of phosphatidylcholine synthesis is mediated via activation of a C/EBP-activating transcription factor-responsive element. J. Biol. Chem. 2004, 279:52007-52015.
35. van Geelen C.M., Pennarun B., Le P.T., de Vries E.G., de Jong S. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5. BMC Cancer 2011, 11:39.
36. Veit B., Yucel J.K., Malhotra V. Microtubule independent vesiculation of Golgi membranes and the reassembly of vesicles into Golgi stacks. J. Cell Biol. 1993, 122:1197-1206.
37. Wang H., Joseph J.A. Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic. Biol. Med. 1999, 27:612-616.
38. Wu X., Lippman S.M. An intermittent approach for cancer chemoprevention. Nat. Rev. Cancer 2011, 11:879-885.
39. Yamaguchi H., Wang H.G. CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J. Biol. Chem. 2004, 279:45495-45502.
40. Yoon M.J., Kang Y.J., Kim I.Y., Kim E.H., Lee J.A., Lim J.H., Kwon T.K., Choi K.S. Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation. Carcinogenesis 2013, 34:1918-1928.